Combined hepatocellular-cholangiocarcinoma An analysis of clinicopathological characteristics after surgery

被引:16
|
作者
Zhang, Hao [1 ]
Yu, Xiaojiong [1 ]
Xu, Jian [1 ]
Li, Juan [2 ,3 ]
Zhou, Yao [1 ]
机构
[1] Univ Elect Sci & Technol China, Hosp 1, Dept Hepatobiliary Surg, 32 West Second Sect First Ring Rd, Chengdu 610041, Sichuan, Peoples R China
[2] Univ Elect Sci & Technol China, Hosp 1, Dept Pathol, Chengdu, Sichuan, Peoples R China
[3] Sichuan Prov Peoples Hosp, 32 West Second Sect First Ring Rd, Chengdu, Sichuan, Peoples R China
关键词
Chinese; hepatectomy; liver cancer; survival rate; CARCINOMA; CELLS; HEPATECTOMY; PROGNOSIS; FEATURES;
D O I
10.1097/MD.0000000000017102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combined hepatocellular-cholangiocarcinoma (CHCC) is a rare type of primary liver cancer (PLC). The aim of this study was to investigate the disease characteristics in CHCC patients and compare them with those in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). The perioperative and follow-up data of CHCC patients (n=15), HCC patients (n=577), and ICC patients (n=61) were retrospectively analyzed, and the clinicopathological characteristics were compared among these 3 groups. In the CHCC group, the serum level of AFP was significantly higher than that of the ICC group (P=.002), and the CA19-9 level was higher than that of the HCC group (P=.011). The positive rates of CK7 and CK19 expression were higher in CHCC group than in HCC group (both P<.001), while the positive rates of Glypican-3 and Hepatocyte expression were higher in CHCC group than in ICC group (both P<.001). Meanwhile, the CHCC patients were likely to have undergone more MJH/LT than the HCC patients (P=.037) and the ICC patients (P=.011). Macrovascular invasion and lymph node metastasis in the CHCC group were significantly higher but satellite lesions were similar, compared to the HCC group. Both the 1-year disease-free survival (DFS) and the 1-year overall survival (OS) for the CHCC patients were worse than those for the HCC patients. AFP >= 400 ng/ml, tumor size >= 5 cm, tumor number >= 2, macro- and microvascular invasion, distant metastasis and positive margin were risk factors for both DFS and OS for the PLC patients. Multivariate analysis also confirmed that ICC and lymph node metastasis were risk factors for DFS and MJH/LT was risk factor for OS. CHCC patients appear to have intermediate clinical characteristics in comparison with the HCC and ICC patients, and the 1-year DFS and OS for the CHCC patients was worse than the HCC patients, but similar to the ICC patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes
    Qian, Ye-Rong
    Jiang, Na
    Liu, Peng
    Zhang, Xu-Feng
    Liu, Xue-Min
    Lv, Yi
    Xiang, Jun-Xi
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2021, 20 (06) : 574 - 578
  • [32] Hepatocellular-cholangiocarcinoma with sarcomatous change:Clinicopathological features and outcomes
    Ye-Rong Qian
    Na Jiang
    Peng Liu
    Xu-Feng Zhang
    Xue-Min Liu
    Yi Lv
    Jun-Xi Xiang
    Hepatobiliary & Pancreatic Diseases International, 2021, 20 (06) : 574 - 578
  • [33] Clinicopathological features of combined hepatocellular-cholangiocarcinoma with sarcomatous change Case report and literature review
    Gu, Qianru
    Yu, Xia
    Chen, Hanbin
    Chen, Guorong
    MEDICINE, 2018, 97 (03)
  • [34] Carcinoma of ectopic liver tissue shares characteristics with combined hepatocellular-cholangiocarcinoma
    Geng, Shi-Kai
    Zhou, Jian-Hong
    Liu, You-Jun
    Xu, Li-Ping
    Wang, Nong-Rong
    Sun, Jian
    Chen, Nan-Ping
    Yu, Xue-Feng
    Deng, Jun
    Yin, Sheng-Jiang
    Wang, Meng-Meng
    Su, Yue
    Lu, Qi
    Qu, Qiang-Guan
    Yi, Fan
    Mei, Jin-Hong
    Feng, Qiong
    Gong, Zhi-Qiang
    Yang, Hong-Wu
    Deng, Huan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (11): : 12142 - 12153
  • [35] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA: AN INDICATION FOR LIVER TRANSPLANTATION?
    Schaefer, I. -M.
    Reinecke, J. A.
    Goralczyk, A.
    Schultze, F. C.
    Amanzada, A.
    Schweyer, S.
    Lorf, T.
    Obed, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 39
  • [36] EXPRESSION OF ABH AND LEWIS BLOOD-GROUP ANTIGENS IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - POSSIBLE EVIDENCE FOR THE HEPATOCELLULAR ORIGIN OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    OKADA, Y
    JINNO, K
    MORIWAKI, S
    MORICHIKA, S
    TORIGOE, SI
    ARIMA, T
    NAGASHIMA, H
    KOPROWSKI, H
    CANCER, 1987, 60 (03) : 345 - 352
  • [37] Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki, M.
    Sato, Y.
    Nakanuma, Y.
    HISTOPATHOLOGY, 2022, 80 (05) : 859 - 868
  • [38] A HISTOCHEMICAL-STUDY ON COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    UEKUSA, T
    MASTUMOTO, T
    ABE, H
    FUKUDA, Y
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 1985, 18 (06) : 673 - 673
  • [39] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1137 - 1139
  • [40] Differential miRNA Analysis of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Pilot Study
    Malik, Preeti
    Huang, Yan
    Castrodad-Rodriguez, Carlos
    Lin, Juan
    Loudig, Olivier
    Bhalla, Amarpreet
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1137 - 1139